Aika
AI-native platform accelerating clinical trial design, feasibility, and regulatory planning
Platform · Cloud SaaSCompany source
Company profile
About Biorce
Biorce is a health technology company that has developed Aika, the first AI-native platform designed to accelerate the clinical trials lifecycle. Founded by Pedro Coelho after his father's terminal diagnosis revealed how inefficient processes delay life-saving treatments, Biorce's mission is to make clinical trials faster, smarter, and fully transparent. Aika unifies solutions for protocol design, feasibility assessment, and regulatory planning in one intuitive, conversational workspace. Unlike traditional black-box AI systems, Aika provides 100% explainable recommendations by cross-referencing approximately one million real clinical trials to identify proven patterns and best practices. The platform enables clinical teams to create protocol first drafts in 2 days instead of 21, complete submission-ready protocols in under 30 days versus 90, and reduce avoidable amendments by 60%. Aika's conversational interface requires no programming expertise, making it accessible to clinicians and trial managers. The platform is GxP-aligned, SOC2 Type II certified, and HIPAA-ready. Biorce serves pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) across the US, EU, and APAC regions. Built by former CRO professionals, clinicians, regulatory experts, and AI leaders, the company has raised $52 million from DST Global and Norrsken VC to reinvent how clinical trials are designed and executed.
Company description Biorce official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Biorce?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Biotechnology firms
- Contract Research Organizations (CROs)
- Pharmaceutical companies
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsAsia-Pacific (APAC) · European Union · United States
Company sourceOfficial website
Company milestones
Platform expansion
Raised $52 million from DST Global and Norrsken VC. Platform being used across US, EU, and APAC by global clinical trial teams. Published transparency report on explainable AI approach.
Partnerships
Recorded partners
- DST Global
- Kinetikos
- Norrsken VC
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
90% faster protocol first draft creation
2 days vs 21 days traditional timeline
8 weeks saved on complete protocol
Less than 30 days vs 90 days traditional timeline
60% reduction in avoidable amendments
Down to 1.5 or fewer vs average 3.3 amendments per trial
95% faster feasibility assessment
Less than 1 day vs up to 4 weeks
$400K average saved per amendment prevented
Cost per amendment up to $450K
$1.2M-$2.4M annual savings
For mid-sized pipeline with 10 trials per year
0 regulatory rejections
100% defensible recommendations
$1.2M saved in Phase II Oncology trial
By eliminating 3 amendments
Top-tier Pharma (anonymized)
Phase II Oncology trial optimization
Eliminated 3 amendments and saved $1.2M
Verified Customer (anonymized)
Clinical trial protocol design and feasibility assessment
Feasibility assessment speed increased by 95% and avoidable amendment reduction was 60%. For a $50K trial, saved $5-8K on setup and $10-20K on fewer amendments
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Pedro Coelho
Founder
06 · Company updates
Updates from Biorce
Recent articles published on Biorce's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.